Jeffrey W. Albers

Insider Reports History

Entity
Individual
Location
Blueprint Medicines Corp., 215 First Street, Suite 340/350, Cambridge, Massachusetts
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Jeffrey W. Albers:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Blueprint Medicines Corp Director Common Stock 167K $17.6M $105.13 Jun 12, 2024 Direct
Spyre Therapeutics, Inc. Director Common Stock 34.4K $24.4K $0.71 Nov 24, 2023 By Sessions LLC
Kymera Therapeutics, Inc. Director Common Stock 0 $0 $39.05 Feb 21, 2024 Direct
Magenta Therapeutics, Inc. Director Stock Option (Right to Buy) 20K Jun 28, 2022 Direct
Kymera Therapeutics, Inc. Director Stock Option (Right to Buy) 16K Jun 18, 2024 Direct
Spyre Therapeutics, Inc. Director Stock Option (Right to Buy) 11.3K May 14, 2024 Direct
Blueprint Medicines Corp Director Stock Option (Right to Buy) 4.57K Jun 12, 2024 Direct
Spyre Therapeutics, Inc. Director Series A Preferred Stock 0 Nov 24, 2023 By Sessions LLC

Insider Reports Filed by Jeffrey W. Albers

Symbol Company Period Transactions Value $ Form Type Date Filed Role
KYMR Kymera Therapeutics, Inc. Jun 18, 2024 1 $0 4 Jun 20, 2024 Director
BPMC Blueprint Medicines Corp Jun 12, 2024 2 $0 4 Jun 14, 2024 Director
SYRE Spyre Therapeutics, Inc. May 14, 2024 1 $0 4 May 16, 2024 Director
BPMC Blueprint Medicines Corp Mar 20, 2024 9 -$2.01M 4 Mar 22, 2024 Director
BPMC Blueprint Medicines Corp Mar 7, 2024 1 -$1M 4 Mar 26, 2024 Director
KYMR Kymera Therapeutics, Inc. Feb 20, 2024 6 -$144K 4 Feb 21, 2024 Director
BPMC Blueprint Medicines Corp Jan 25, 2024 8 -$1.87M 4 Jan 29, 2024 Director
KYMR Kymera Therapeutics, Inc. Jan 23, 2024 3 -$197K 4 Jan 23, 2024 Director
BPMC Blueprint Medicines Corp Dec 11, 2023 3 -$215K 4 Dec 13, 2023 Director
BPMC Blueprint Medicines Corp Nov 30, 2023 3 -$173K 4 Dec 4, 2023 Director
BPMC Blueprint Medicines Corp Nov 24, 2023 4 -$985K 4 Nov 28, 2023 Director
SYRE Spyre Therapeutics, Inc. Nov 22, 2023 3 $0 4/A Dec 8, 2023 Director
SYRE Spyre Therapeutics, Inc. Nov 22, 2023 0 $0 3/A Dec 8, 2023 Director
BPMC Blueprint Medicines Corp Nov 1, 2023 10 -$241K 4 Nov 3, 2023 Director
BPMC Blueprint Medicines Corp Sep 27, 2023 8 -$1.2M 4 Sep 29, 2023 Director
BPMC Blueprint Medicines Corp Aug 24, 2023 6 -$1.2M 4 Aug 28, 2023 Director
BPMC Blueprint Medicines Corp Jun 21, 2023 2 $0 4 Jun 23, 2023 Director
KYMR Kymera Therapeutics, Inc. Jun 15, 2023 1 $0 4 Jun 20, 2023 Director
BPMC Blueprint Medicines Corp Mar 6, 2023 2 -$447K 4 Mar 8, 2023 Director
BPMC Blueprint Medicines Corp Dec 5, 2022 5 -$833K 4 Dec 7, 2022 Director
BPMC Blueprint Medicines Corp Aug 19, 2022 7 -$554K 4 Aug 23, 2022 Director
BPMC Blueprint Medicines Corp Aug 16, 2022 7 -$1.2M 4 Aug 18, 2022 Director
BPMC Blueprint Medicines Corp Aug 8, 2022 5 -$632K 4 Aug 10, 2022 Director
MGTA Magenta Therapeutics, Inc. Jun 28, 2022 1 $0 4 Jun 30, 2022 Director
KYMR Kymera Therapeutics, Inc. Jun 15, 2022 1 $0 4 Jun 16, 2022 Director
BPMC Blueprint Medicines Corp May 16, 2022 7 -$949K 4 May 18, 2022 Director
BPMC Blueprint Medicines Corp Apr 6, 2022 3 -$276K 4 Apr 8, 2022 CEO AND PRESIDENT, Director
BPMC Blueprint Medicines Corp Mar 3, 2022 10 -$1.69M 4 Mar 8, 2022 CEO AND PRESIDENT, Director
BPMC Blueprint Medicines Corp Mar 1, 2022 2 $0 4 Mar 3, 2022 CEO AND PRESIDENT, Director
BPMC Blueprint Medicines Corp Nov 15, 2021 8 -$3.08M 4 Nov 17, 2021 CEO and President, Director
BPMC Blueprint Medicines Corp Nov 1, 2021 3 -$501K 4 Nov 3, 2021 CEO and President, Director
BPMC Blueprint Medicines Corp Aug 26, 2021 2 $29.9K 4 Aug 30, 2021 CEO and President, Director
BPMC Blueprint Medicines Corp Aug 19, 2021 6 -$2.04M 4 Aug 23, 2021 CEO and President, Director
KYMR Kymera Therapeutics, Inc. Jun 16, 2021 1 $0 4 Jun 17, 2021 Director
MGTA Magenta Therapeutics, Inc. Jun 1, 2021 1 $0 4 Jun 3, 2021 Director
BPMC Blueprint Medicines Corp May 12, 2021 7 -$2.04M 4 May 14, 2021 CEO and President, Director